April 2008 Meeting

Strategies for Extending the Linear Dynamic Range in LC/MS/MS Experiments.

The April 2008 CSSC meeting will be held at the 95 Gathering Place in Wallingford, CT.  The meeting will feature a technical presentation by Dr. Michael Donegan of Bristol-Myers Squibb in Wallingford, Connecticut, as well as dinner.  The cost of the meeting is $30 ($15 Students and Emeritus) and is to be paid at the event.

You can still register for April's meeting.

To use the online system, you must be registered as a user.
Click here to become a registered user.

Click here for a printable version of this announcement

Abstract:  

The sensitivity of modern LC/MS/MS instrumentation is quite remarkable when compared to what was available just 10 years ago.  The one drawback to this explosion of sensitivity is that the linear dynamic range response has not kept pace with sensitivity advances.  As was the case 10 years ago, bioanalytical researchers can expect 3-4 orders of magnitude of linear dynamic range regardless of where the lower limit of quantitation (LLOQ) starts.  Recently, we evaluated an LC system from Eksigent Technologies that was capable of delivering extraordinarily accurate flow rates and extremely low injection volumes (from 100 nL to 1 mL).  By accurately changing injection volumes, we were able to prevent saturation and extend the linear dynamic range to 50,000 nM for the three compounds (buspirone, terfenadine and dextromethorphan) analyzed in this study. 

Biography:

 Dr. Michael Donegan is a Senior Research Investigator in the preclinical discovery bioanalytical group at Bristol-Myers Squibb in Wallingford, Connecticut

Michael Donegan attended Rutgers University and obtained his undergraduate degree in Chemistry in 1988.  He then attended Philadelphia College of Pharmacy and Science where he obtained his Ph.D. in Medicinal Chemistry in 1995.  After a brief postdoctoral position at Thomas Jefferson University, Michael started work at a small biotech company, West Pharmaceuticals, leading a bioanalytical group in support of an IND.  In 1999, Michael left the Philadelphia area to move to Massachusetts and started working at Applied Biosystems doing applications research in their Framingham facility.  This position enabled Dr.Donegan to meet and develop collaborations with MS users from many different areas of scientific interest.  After 6 years, Michael left Applied Biosystems and took a position as Senior Research Investigator in the preclinical discovery bioanalytical group at Bristol-Myers Squibb in Wallingford, CT.  In his brief role at BMS, Michael has implemented UPLC into the bioanalytical laboratory, trained many MS users, and started a research program for better, more efficient bioanalytical methodology. 

95 Gathering Place
865 North Colony Road
Wallingford, CT 06492
(203) 265-1552

Last Updated:  04/28/2008 05:47 PM